Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2009.

Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $33.4 million or $0.36 per share in the second quarter of 2008.

Nektar made improvements to its operating efficiencies as compared to a year ago. Total operating costs and expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in the second quarter of 2008. For the first half of 2009, total operating costs and expenses were down 28% to $83.5 million as compared to $115.6 million in the first half of 2008.

"In the first half of 2009, we made a strong commitment to advancing our clinical pipeline," stated Howard W. Robin, President and Chief Executive Officer of Nektar. "We completed our Phase 2 clinical program for NKTR-118, and we are poised to report Phase 2 data for NKTR-102 and Phase 1 data for NKTR-105 by year-end. These achievements underscore the strength of Nektar's drug development organization and our successful strategy to focus on developing proprietary drugs with our advanced polymer conjugate technology."

Research and development expense was $24.2 million in the second quarter of 2009 as compared to $33.5 million for the same quarter in 2008. For the first half of 2009, research and development expense was $48.0 million as compared to $70.9 million for the first half of 2008. Included in the $48.0 million of overall research and development expense in the first half of 2009 is approximately $27.4 million of investment in Nektar preclinical and clinical development programs.

Revenue for the three month period ende
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 Delcath ... medical technology company testing its proprietary treatment system ... announced today the signing of its first research, ... Hepatic Perfusion (PHP) System  (the Delcath PHP System™). ... exclusive right to market and sell the Delcath ...
(Date:2/9/2010)... , Feb. 9 Palatin ... announced the completion of first cohort dosing in ... experimental treatment for sexual dysfunction.  The primary endpoint ... blood pressure effects of subcutaneous bremelanotide in men ... will also evaluate consistency of plasma exposure of ...
(Date:2/8/2010)... Calif. , Feb. 8 PreXion, ... quality 3D Cone Beam Imaging systems for dentistry, today ... as Director of Marketing. ,, PreXion President/COO ... Keith on our senior management team and I look ... extensive sales and marketing leadership, experience and success in ...
Breaking Medicine Technology:Delcath Signs First Partner Agreement in Asia 2Delcath Signs First Partner Agreement in Asia 3Delcath Signs First Partner Agreement in Asia 4Delcath Signs First Partner Agreement in Asia 5Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4PreXion, Inc. Announces Appointment of Director of Marketing 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 1BayCare Named CIO 100 Award Winner by CIO Magazine 47458 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 3NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 1FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 2FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 4FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 5FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 6FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 7
... - Research Collaboration to ... Jubilant Organosys Ltd, headquartered in ... Biosys Ltd, has signed a research,collaboration agreement with, ... the international pharmaceutical company,s pre-clinical,pipeline. Under the shared ...
... concludes that new cosmeceutical improves skin barrier function, erythema ... Senetek PLC (OTC Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, today ... Lotion for Improving the Signs and Symptoms of Rosacea," ...
Other Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2
(Date:2/9/2010)... SAINT PAUL, Minn. , Feb. 9 ... death, chronic obstructive pulmonary disease (COPD), is now ... Environmental Public Health Tracking Program. The program focuses ... Minnesota that can be triggered or made ... or outdoor air pollution — asthma, heart attacks ...
(Date:2/9/2010)... for the Heart with ... , Feb. 9 Show your ... gift for the heart with the new ... Recipes Made with Canola Oil" by the American Diabetes ... these recipes for love or give the cookbook as ...
(Date:2/9/2010)... In conjunction with the 2010 Super Bowl, on Feb. ... first-annual Gridiron Greats Night of Champions, a charitable event for ... and Jamie Foxx . Supported by more than ... non-profit organization that provides financial assistance and social services to ... Greats recognized LSI at the event as Medical Partner of ...
(Date:2/9/2010)... (Boston)- Researchers from Boston University,s Slone Epidemiology Center ... status and risk for type 2 diabetes in ... the online American Journal of Epidemiology , ... relationship between neighborhood socioeconomic status and incidence of ... cohort of African-American women. , Type 2 diabetes ...
(Date:2/9/2010)... at the Ireland Cancer Center of University Hospitals (UH) ... lead to a new standard of care for patients ... the February issue of Clinical Cancer Research, ... medicine, Triapine, was well tolerated in combination with standard-of-care ... cancer. This regimen provided both significant reduction in cancer ...
Breaking Medicine News(10 mins):Health News:Minnesota Department of Health Report: Nearly 6,000 Hospitalizations for COPD in 2007 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Laser Spine Institute Honored at the Gridiron Greats Night of Champions 2Health News:Neighborhood socioeconomic status and diabetes 2
... . , May 29 Landauer, Inc. (NYSE: ... named Chief Nuclear Executive, effective May 15, 2009. Gipson ... "We are very pleased to be able to name ... industry experience at the executive and operating level and will ...
... The British Red Cross are asking people,to pledge their ... social networks, instant messenger and email during,Refugee Week (15th-21st June). ... that a charity has created an online movement to,pledge support ... Refugees arriving in the UK are often labelled as ...
... urges president to learn from their proven preventive approach to solve ... ... (PRWEB) May 29, 2009 -- Cenegenics® Medical Institute, global age management ... a White House interview that he,s "absolutely committed" to a healthcare ...
... First in a Series of Community Discussions on Improving ... 28 Teva Pharmaceuticals USA, the leading generic pharmaceutical ... community roundtables as part of their Year of Affordable ... held at the YMCA San Francisco, aimed at raising ...
... the UltraPulse CO2 fractional laser as a Miracle Treatment for Burn ... will also be featuring the treatment tonight, check your local listings ... by The Insider . The interview focused on how and ... years. The girls also discussed their journey through the treatment process ...
... Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging ... 41 Direct, Inc. (CK41), the Company,s joint venture marketing ... updated its product launch plans. The previously announced mid-May ... Savage, CK41,s new Chief Executive Officer, to impart his ...
Other Medicine News:Health News:Landauer Names Douglas R. Gipson Chief Nuclear Executive 2Health News:Global Creative, Media and Technology Agency LBi Launches Cutting Edge Social Movement for the British Red Cross in Support of Refugee Week 2Health News:Cenegenics Poses Challenge to Obama for Successful Healthcare Reform 2Health News:Cenegenics Poses Challenge to Obama for Successful Healthcare Reform 3Health News:Cenegenics Poses Challenge to Obama for Successful Healthcare Reform 4Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 2Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 4
... many years experience in the field of Urodynamics, ... Urodynamics Chair. Our new chair is manufactured from ... of Urodynamic studies can be improved considerably if ... the test, and this aspect was given a ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... Osmometer provides extremely accurate osmolality measurements ... These results are obtained by using ... total concentration. Only the model 2020 ... sample handling, and flexible reporting options ...
Medicine Products: